Drugs / TORL-1-23
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05103683 | Nov 2021 → Aug 2026 overdue | endometrial cancer, non-small cell lung carcinoma, ovarian cancer | TORL Biotherapeutics, LLC | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07322094 | Dec 2025 → Dec 2027 expected | fallopian tube carcinoma, primary peritoneal carcinoma, uterine adnexa cancer | TORL Biotherapeutics, LLC | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06690775 | Nov 2024 → Oct 2027 expected | fallopian tube cancer, ovarian endometrial cancer, primary peritoneal carcinoma | TORL Biotherapeutics, LLC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TORL-1-23 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07322094 ↗ |
| Modality | Other / unclassified | “antibody drug conjugate (ADC)” NCT05103683 ↗ |
| Route | Intravenous | “2.4mg/kg intravenous infusion” NCT06690775 ↗ |